12/1/2008
Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
Presentation to Highlight Results of Ocular Neuroprotection Candidate
10/13/2008
Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Quark siRNAs Examined Alone and in Combination with Chemotherapy
9/25/2008
Quark Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Data Validates Neuroprotective Effect of Quark’s New RNAi product on dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma
9/17/2008
Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
7/30/2008
Quark Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in DME
Clinical Program Leverages Quark’s RNAi Technology
4/7/2008
Quark Receives FDA Approval of IND For Kidney Transplant
Quark’s second siRNA drug delivered systemically
4/7/2008
Quark Closes $27 Million Financing
Funds Will Support Clinical Development of Pipeline Products
12/23/2007
Quark to Present at JPMorgan 26th Annual Healthcare Conference
Quark Pharmaceuticals to Present New Preclinical Proof of Concept Results at JPMorgan 26th Annual Healthcare Conference
11/19/2007
Quark Announces First Systemic siRNA Dosing
Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans. Commences Phase I Clinical Trial of Proprietary siRNA Molecule in Acute Renal Failure.
10/23/2007
Quark to Present at CIBC and Acumen BioFin Rodman & Renshaw
Quark Pharmaceuticals to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10/10/2007
Development Milestone Payment from Mitsubishi
Quark Pharmaceuticals, Inc. to Receive Development Milestone Payment from Mitsubishi Pharma Corporation
9/25/2007
Development of Proprietary siRNA Compounds for Noise-Induced Hearing Loss
Quark Pharmaceuticals Signs Collaboration Agreement with University of Michigan for Development of Proprietary siRNA Compounds for Noise-Induced Hearing Loss
8/21/2007
Agreement with University of NY
Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
8/6/2007
Positive Preclinical Results
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Quark to initiate Phase 1 trial of AKIi-5 as the first human clinical study involving the systemic delivery of siRNA
9/26/2006
Pfizer and Quark
Pfizer expands research commitment to ophthalmology through licensing agreement with quark biotech...
6/19/2005
COPD
Quark Biotech Discovers Role of RTP801 as Signaling Molecule in Cigarette Smoking-Induced Pulmonary Injury...